VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
Summary
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once daily.
Timeline
- Start
- 2024-12-18
- Primary completion
- 2025-06-24
- Completion
- 2025-08-15
Outcome
Met primary endpoint
release “The Phase 2 VENTURE-Oral Dosing trial successfully achieved its primary and secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight.” vikingtherapeutics.com ↗
release “Phase 2 VENTURE-Oral Dosing study of VK2735, which successfully achieved its primary and secondary endpoints” vikingtherapeutics.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VK2735 | Peptide | — | — |
Indications
No indication recorded.